Drug profile · INN
blonanserin
LONASEN PARTIAL CHANGE APPROVAL
blonanserin (LONASEN PARTIAL CHANGE APPROVAL) is a serotonin 2a (5-ht2a) receptor antagonist.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — blonanserin
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
blonanserin (LONASEN PARTIAL CHANGE APPROVAL) is a serotonin 2a (5-ht2a) receptor antagonist.
Key facts
INN blonanserin
Brand LONASEN PARTIAL CHANGE APPROVAL
Mechanism Serotonin 2a (5-HT2a) receptor antagonist
Target D(2) dopamine receptor
Mechanism of action
Serotonin 2a (5-HT2a) receptor antagonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is blonanserin?
blonanserin (LONASEN PARTIAL CHANGE APPROVAL) is a serotonin 2a (5-ht2a) receptor antagonist.
What is the brand name for blonanserin?
LONASEN PARTIAL CHANGE APPROVAL is a marketed brand name for blonanserin. Check FDA Drugs@FDA for the current US label holder and prescribing information.